Recruiting
Phase 1

ALV-100

Sponsor:

Alveus Therapeutics, Inc.

Code:

NCT07399678

Conditions

Overweight or Obese Adults

Overweight or Obese, Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

ALV-100

Placebo

Study Details

Brief summary:

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Conditions

Overweight or Obese Adults

Overweight or Obese, Type 2 Diabetes

Study ID

NCT07399678

Start date

Dec 29, 2025

Status verified date

Jul, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Apr, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

For Part A and B

  • Adult male and female participants, aged 18 to 65 years, inclusive, at the time of signing the informed consent form
  • Body mass index between 27.0 to 39.9 kg/m2 at Screening, both inclusive; overweight should be due to excess adipose tissue, as judged by the Investigator.
  • Have a stable body weight (< 5.0 kg/11 lbs self-reported change) within 90 days prior to Screening
  • Females must be surgically sterile (by means of bilateral salpingectomy, hysterectomy or bilateral oophorectomy) or be post-menopausal (defined as spontaneous cessation of menses for at least 1 year prior to Screening). Females who are post-menopausal and < 55 years must have a follicle-stimulating hormone level > 40 IU/L at Screening.
  • Males with female partners of child-bearing potential must be willing to practice abstinence or must agree to use condom as contraception throughout the duration of the study. This criterion may be waived for male participants who have had a documented successful vasectomy > 6 months before signing the ICF.

For Part B only

  • Diagnosis of Type 2 Diabetes for at least 180 days prior to Screening.
  • Glycemic control managed by diet and exercise alone or by stable treatment with metformin and/or sodium-glucose cotransporter 2 inhibitors (SGLT-2i), with no dose changes within 3 months prior to Screening.
  • Hemoglobin A1c (HbA1c) between 6.5 % and 9.0% (equivalent to 48-75 mmol/mol), both inclusive, at Screening.

Exclusion Criteria:

For Part A and B

  • History or presence of any clinically relevant respiratory, metabolic (including dyslipidemia, however screening total cholesterol below or equal to 302 mg/dL (7.8 mmol/L) and/or screening triglyceride below or equal to 500 mg/dL (5.65 mmol/L) is accepted), renal, hepatic, gastrointestinal, endocrinological conditions (except conditions associated with type 2 diabetes in Part B) at the discretion of the Investigator.
  • Participants with a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 or a personal history of nonfamilial medullary thyroid carcinoma.
  • Current or history of chronic or acute pancreatitis.
  • Obesity caused by known endocrinologic disorders (e.g., Cushing syndrome) or monogenetic or syndromic forms of obesity (for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndrome).
  • History of major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or anxiety disorder).
  • Lifetime history of a suicide attempt or of any suicidal behavior by endorsement of (answered yes to) any of the items in the suicidal behavior section on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening.
  • Systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg at Screening.
  • History of or current cardiovascular disease, including but not limited to stable and unstable angina, myocardial infarction, congestive heart failure, transient ischemic attack, stroke, clinically significant arrhythmias and conduction disorders or venous thromboembolism.

Part A only

• History or clinical evidence of Type 1 or Type 2 diabetes mellitus, including HbA1c ≥ 6.5% and/or a fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) at Screening (female participants with a history of gestational diabetes are allowed).

Part B only

  • Fasting plasma glucose (FPG) > 270 mg/dL (15.0 mmol/L) at Screening.
  • Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (within1.5 years from Screening) ophthalmologic examination.
  • Severe neuropathy as judged by the investigator.
  • Advanced nephropathy (defined as albuminuria ≥ 300 mg/g).
  • History of severe hypoglycemia or hypoglycemic unawareness as judged by the investigator.

Study Design

Enrollment

180 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A - Cohort 1 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

placebo comparator: Part A - Cohort 1 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

experimental: Part A - Cohort 2 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

placebo comparator: Part A - Cohort 2 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

experimental: Part A - Cohort 3 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

placebo comparator: Part A - Cohort 3 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

experimental: Part A - Cohort 4 (ALV-100)

Participants with overweight or obesity without type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

placebo comparator: Part A - Cohort 4 (Placebo)

Participants with overweight or obesity without type 2 diabetes will receive placebo by subcutaneous injection.

experimental: Part B - T2D Cohort (ALV-100)

Participants with overweight or obesity with type 2 diabetes will receive ascending doses of ALV-100 by subcutaneous injection.

placebo comparator: Part B - T2D Cohort (Placebo)

Participants with overweight or obesity with type 2 diabetes will receive placebo by subcutaneous injection.

Interventions

ALV-100

Participants will receive multiple ascending doses of ALV-100.

Placebo

Participants will receive placebo matching ALV-100, volume-matched to active dose.

Primary outcome measure

  • Safety and tolerability [ Time Frame: From First Dose to Week 52 ]

Central Contacts and Locations

Central contacts

Study Director

+1 215-607-2243clinicaltrials@alveustx.com

Locations

Clinical Pharmacology of Miami

Recruiting

Miami, Florida, United States, 33172

Ohio Clinical Trials

Recruiting

Columbus, Ohio, United States, 43212

More Information

Sponsor

Alveus Therapeutics, Inc.

Last update posted

Jul 23, 2026

Last verified

Jul, 2026

Keywords

  • Overweight, Obese, Obesity, Type 2 Diabetes, Weight loss

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Alveus Therapeutics, Inc. on 2026-07-23.